Related Experiment Videos
[How long should antithrombotic therapy be continued following aortocoronary bypass surgery?]
M Pfisterer1, G Jockers, S Regenass
1Departement Innere Medizin, Universitätskliniken Basel.
Insights
Prolonged antithrombotic therapy, including aspirin and dipyridamole, significantly reduces late bypass-graft occlusion after coronary artery bypass grafting (CABG) surgery. Continued treatment for at least one year is recommended over a 3-month duration.
Area of Science:
- Cardiovascular Surgery
- Pharmacology
- Clinical Trials
Background:
- Late bypass-graft occlusion is a significant complication following Coronary Artery Bypass Grafting (CABG) surgery.
- Antithrombotic therapy is commonly used post-CABG, but optimal duration remains debated.
Purpose of the Study:
- To evaluate the effect of prolonged antithrombotic treatment on late bypass-graft occlusion after CABG.
- To compare the efficacy of continued antithrombotic therapy versus placebo beyond 3 months post-surgery.
Main Methods:
- Prospective randomized trial involving patients undergoing CABG.
- Patients received active antithrombotic treatment (aspirin + dipyridamole) for 3 months, then were randomized to continued active treatment or placebo for up to 12 months.
- Angiographic assessments were performed at 2 weeks and 12 months postoperatively to determine graft occlusion.
Main Results:
- A significantly lower rate of new graft occlusions was observed with continued antithrombotic therapy (8%) compared to placebo (14%) between 2 weeks and 12 months post-CABG (p = 0.03).
- This benefit was more pronounced for individual grafts (6% vs 12%, p = 0.01).
- Fewer patients on 12 months of active therapy had at least one occluded graft (22% vs 32%, p = 0.08).
Conclusions:
- Antithrombotic treatment should be continued for at least one year after CABG surgery, not halted at 3 months.
- Prolonged use of aspirin and dipyridamole demonstrates efficacy in preventing late bypass-graft occlusion.
- Findings support extended antithrombotic therapy to improve long-term outcomes in CABG patients.
Abstract:
In a prospective randomized trial the effect of prolonged antithrombotic treatment with anticoagulants or antiplatelet drugs (50 mg aspirin + 400 mg dipyridamole daily) on late bypass-graft occlusion was studied. After 3 months active treatment was replaced by placebo in half of the patients. Between the angiographic checkups 2 weeks and 12 months postoperatively, 28/330 (8%) new graft occlusions had occurred on continued therapy, versus 44/319 (14%) on placebo (p = 0.03). This difference was most pronounced in individual grafts (6% vs 12%, p = 0.01), so that fewer patients with 12 months' active therapy had at least one occluded graft (22% versus 32%, p = 0.08). These findings suggest that antithrombotic treatment should not be halted 3 months after CABG surgery but should be continued for at least one year and possibly longer.